31P and 1H MRS of DB-1 melanoma xenografts: Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan

Kavindra Nath, David S. Nelson, Andrew M. Ho, Seung Cheol Lee, Moses M. Darpolor, Stephen Pickup, Rong Zhou, Daniel F. Heitjan, Dennis B. Leeper, Jerry D. Glickson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In vivo 31P MRS demonstrates that human melanoma xenografts in immunosuppressed mice treated with lonidamine (LND, 100mg/kg intraperitoneally) exhibit a decrease in intracellular pH (pHi) from 6.90±0.05 to 6.33±0.10 (p<0.001), a slight decrease in extracellular pH (pHe) from 7.00±0.04 to 6.80±0.07 (p>0.05) and a monotonic decline in bioenergetics (nucleoside triphosphate/inorganic phosphate) of 66.8±5.7% (p<0.001) relative to the baseline level. Both bioenergetics and pHi decreases were sustained for at least 3h following LND treatment. Liver exhibited a transient intracellular acidification by 0.2±0.1 pH units (p>0.05) at 20min post-LND, with no significant change in pHe and a small transient decrease in bioenergetics (32.9±10.6%, p>0.05) at 40min post-LND. No changes in pHi or adenosine triphosphate/inorganic phosphate were detected in the brain (pHi, bioenergetics; p>0.1) or skeletal muscle (pHi, pHe, bioenergetics; p>0.1) for at least 120min post-LND. Steady-state tumor lactate monitored by 1H MRS with a selective multiquantum pulse sequence with Hadamard localization increased approximately three-fold (p=0.009). Treatment with LND increased the systemic melanoma response to melphalan (LPAM; 7.5mg/kg intravenously), producing a growth delay of 19.9±2.0days (tumor doubling time, 6.15±0.31days; log10 cell kill, 0.975±0.110; cell kill, 89.4±2.2%) compared with LND alone of 1.1±0.1days and LPAM alone of 4.0±0.0days. The study demonstrates that the effects of LND on tumor pHi and bioenergetics may sensitize melanoma to pH-dependent therapeutics, such as chemotherapy with alkylating agents or hyperthermia.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalNMR in Biomedicine
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Melphalan
Heterografts
Energy Metabolism
Tumors
Melanoma
Neoplasms
Phosphates
Chemotherapy
Alkylating Agents
Nucleosides
Muscle
Lactic Acid
Brain
Skeletal Muscle
Fever
Adenosine Triphosphate
lonidamine
Proton Magnetic Resonance Spectroscopy
Drug Therapy
Therapeutics

Keywords

  • P MRS
  • Lonidamine
  • Melanoma
  • Melphalan
  • Monocarboxylic acid transporter
  • Tumor acidification

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Spectroscopy

Cite this

31P and 1H MRS of DB-1 melanoma xenografts : Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. / Nath, Kavindra; Nelson, David S.; Ho, Andrew M.; Lee, Seung Cheol; Darpolor, Moses M.; Pickup, Stephen; Zhou, Rong; Heitjan, Daniel F.; Leeper, Dennis B.; Glickson, Jerry D.

In: NMR in Biomedicine, Vol. 26, No. 1, 01.01.2013, p. 98-105.

Research output: Contribution to journalArticle

Nath, Kavindra ; Nelson, David S. ; Ho, Andrew M. ; Lee, Seung Cheol ; Darpolor, Moses M. ; Pickup, Stephen ; Zhou, Rong ; Heitjan, Daniel F. ; Leeper, Dennis B. ; Glickson, Jerry D. / 31P and 1H MRS of DB-1 melanoma xenografts : Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. In: NMR in Biomedicine. 2013 ; Vol. 26, No. 1. pp. 98-105.
@article{2ea93cd56cba467695dc77bee4adcf31,
title = "31P and 1H MRS of DB-1 melanoma xenografts: Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan",
abstract = "In vivo 31P MRS demonstrates that human melanoma xenografts in immunosuppressed mice treated with lonidamine (LND, 100mg/kg intraperitoneally) exhibit a decrease in intracellular pH (pHi) from 6.90±0.05 to 6.33±0.10 (p<0.001), a slight decrease in extracellular pH (pHe) from 7.00±0.04 to 6.80±0.07 (p>0.05) and a monotonic decline in bioenergetics (nucleoside triphosphate/inorganic phosphate) of 66.8±5.7{\%} (p<0.001) relative to the baseline level. Both bioenergetics and pHi decreases were sustained for at least 3h following LND treatment. Liver exhibited a transient intracellular acidification by 0.2±0.1 pH units (p>0.05) at 20min post-LND, with no significant change in pHe and a small transient decrease in bioenergetics (32.9±10.6{\%}, p>0.05) at 40min post-LND. No changes in pHi or adenosine triphosphate/inorganic phosphate were detected in the brain (pHi, bioenergetics; p>0.1) or skeletal muscle (pHi, pHe, bioenergetics; p>0.1) for at least 120min post-LND. Steady-state tumor lactate monitored by 1H MRS with a selective multiquantum pulse sequence with Hadamard localization increased approximately three-fold (p=0.009). Treatment with LND increased the systemic melanoma response to melphalan (LPAM; 7.5mg/kg intravenously), producing a growth delay of 19.9±2.0days (tumor doubling time, 6.15±0.31days; log10 cell kill, 0.975±0.110; cell kill, 89.4±2.2{\%}) compared with LND alone of 1.1±0.1days and LPAM alone of 4.0±0.0days. The study demonstrates that the effects of LND on tumor pHi and bioenergetics may sensitize melanoma to pH-dependent therapeutics, such as chemotherapy with alkylating agents or hyperthermia.",
keywords = "P MRS, Lonidamine, Melanoma, Melphalan, Monocarboxylic acid transporter, Tumor acidification",
author = "Kavindra Nath and Nelson, {David S.} and Ho, {Andrew M.} and Lee, {Seung Cheol} and Darpolor, {Moses M.} and Stephen Pickup and Rong Zhou and Heitjan, {Daniel F.} and Leeper, {Dennis B.} and Glickson, {Jerry D.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/nbm.2824",
language = "English (US)",
volume = "26",
pages = "98--105",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - 31P and 1H MRS of DB-1 melanoma xenografts

T2 - Lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan

AU - Nath, Kavindra

AU - Nelson, David S.

AU - Ho, Andrew M.

AU - Lee, Seung Cheol

AU - Darpolor, Moses M.

AU - Pickup, Stephen

AU - Zhou, Rong

AU - Heitjan, Daniel F.

AU - Leeper, Dennis B.

AU - Glickson, Jerry D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - In vivo 31P MRS demonstrates that human melanoma xenografts in immunosuppressed mice treated with lonidamine (LND, 100mg/kg intraperitoneally) exhibit a decrease in intracellular pH (pHi) from 6.90±0.05 to 6.33±0.10 (p<0.001), a slight decrease in extracellular pH (pHe) from 7.00±0.04 to 6.80±0.07 (p>0.05) and a monotonic decline in bioenergetics (nucleoside triphosphate/inorganic phosphate) of 66.8±5.7% (p<0.001) relative to the baseline level. Both bioenergetics and pHi decreases were sustained for at least 3h following LND treatment. Liver exhibited a transient intracellular acidification by 0.2±0.1 pH units (p>0.05) at 20min post-LND, with no significant change in pHe and a small transient decrease in bioenergetics (32.9±10.6%, p>0.05) at 40min post-LND. No changes in pHi or adenosine triphosphate/inorganic phosphate were detected in the brain (pHi, bioenergetics; p>0.1) or skeletal muscle (pHi, pHe, bioenergetics; p>0.1) for at least 120min post-LND. Steady-state tumor lactate monitored by 1H MRS with a selective multiquantum pulse sequence with Hadamard localization increased approximately three-fold (p=0.009). Treatment with LND increased the systemic melanoma response to melphalan (LPAM; 7.5mg/kg intravenously), producing a growth delay of 19.9±2.0days (tumor doubling time, 6.15±0.31days; log10 cell kill, 0.975±0.110; cell kill, 89.4±2.2%) compared with LND alone of 1.1±0.1days and LPAM alone of 4.0±0.0days. The study demonstrates that the effects of LND on tumor pHi and bioenergetics may sensitize melanoma to pH-dependent therapeutics, such as chemotherapy with alkylating agents or hyperthermia.

AB - In vivo 31P MRS demonstrates that human melanoma xenografts in immunosuppressed mice treated with lonidamine (LND, 100mg/kg intraperitoneally) exhibit a decrease in intracellular pH (pHi) from 6.90±0.05 to 6.33±0.10 (p<0.001), a slight decrease in extracellular pH (pHe) from 7.00±0.04 to 6.80±0.07 (p>0.05) and a monotonic decline in bioenergetics (nucleoside triphosphate/inorganic phosphate) of 66.8±5.7% (p<0.001) relative to the baseline level. Both bioenergetics and pHi decreases were sustained for at least 3h following LND treatment. Liver exhibited a transient intracellular acidification by 0.2±0.1 pH units (p>0.05) at 20min post-LND, with no significant change in pHe and a small transient decrease in bioenergetics (32.9±10.6%, p>0.05) at 40min post-LND. No changes in pHi or adenosine triphosphate/inorganic phosphate were detected in the brain (pHi, bioenergetics; p>0.1) or skeletal muscle (pHi, pHe, bioenergetics; p>0.1) for at least 120min post-LND. Steady-state tumor lactate monitored by 1H MRS with a selective multiquantum pulse sequence with Hadamard localization increased approximately three-fold (p=0.009). Treatment with LND increased the systemic melanoma response to melphalan (LPAM; 7.5mg/kg intravenously), producing a growth delay of 19.9±2.0days (tumor doubling time, 6.15±0.31days; log10 cell kill, 0.975±0.110; cell kill, 89.4±2.2%) compared with LND alone of 1.1±0.1days and LPAM alone of 4.0±0.0days. The study demonstrates that the effects of LND on tumor pHi and bioenergetics may sensitize melanoma to pH-dependent therapeutics, such as chemotherapy with alkylating agents or hyperthermia.

KW - P MRS

KW - Lonidamine

KW - Melanoma

KW - Melphalan

KW - Monocarboxylic acid transporter

KW - Tumor acidification

UR - http://www.scopus.com/inward/record.url?scp=84871706468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871706468&partnerID=8YFLogxK

U2 - 10.1002/nbm.2824

DO - 10.1002/nbm.2824

M3 - Article

C2 - 22745015

AN - SCOPUS:84871706468

VL - 26

SP - 98

EP - 105

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 1

ER -